A guide to reducing the risk of 25 G surgery

Article

Dr Richard Kaiser outlines the recommendations of the microsurgical safety task force.

Key Points

The increasing trend towards microincision surgery is evident across several branches of ophthalmology, vitrectomy surgery included. As with most evolutionary routes, the transition to minimally invasive vitrectomy surgery (MIVS) has not been a smooth one, with new techniques and instruments enjoying their fair share of bad press in recent years.

Endophthalmitis risk too high to ignore

Having read similar reports elsewhere, Dr Kaiser set up the Micro-Surgical Safety Task Force, the aim of the team being to develop a set of recommendations to attempt to reduce the seemingly higher rate of endophthalmitis associated with 25 G vitrectomy. "The task force did not intend to come up with the solution to eliminating all risks associated with 25 G surgery but, between the members, there are a lot of years of experience," remarked Dr Kaiser. The team is comprised of 12 experienced retina surgeons, including George Williams, Antonio Capone, Robert Avery, Harry Flynn, and Ingrid Scott.

According to Dr Kaiser, the answer does not lie in the instrumentation; rather, it lies in the surgical technique.

"Before we put together a list of recommendations, we met several times, for hours at a time. We analyzed the technique in great detail to see if we could identify steps that could be improved or altered in order to reduce the risk of endophthalmitis," said Dr Kaiser.

The recommendations

The team developed recommendations. The following are some of the highlights:

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.